When a Protocol, Investigator’s Brochure (IB), or another clinical development document is delayed, the most intuitive reaction is often: “Is the writing taking too long?” But in actual clinical development work, the causes of document delays often emerge long before a writer begins drafting. The data have not been fully organized. Different versions conflict with one another. A key decision has not yet been finalized. Input from a functional team is still pending. In some cases, no one is entirely clear which source should be treated as authoritative. Under these conditions, adding more writers to the project does not necessarily make the document move faster. Being Writing-Ready Is Not the Same as Having Data A development team may have accumulated a substantial amount of research data and still not be ready to begin formal document development. That is because documents require more than information. They require usable inputs. For example: Is the source clearly identified? Has the version been fixed? Are numerical values consistent across reports? Which information is final? Which information is still preliminary? If conflicting information is identified, who is responsible for resolving it? If these questions remain unresolved, writers will repeatedly need to stop and seek clarification after drafting has begun. The writing cycle may therefore appear long, when much of that time is actually being spent waiting for inputs, confirming versions, and revising content in response to changing information. The First Step in Document Development Is Assessing Readiness Adding a readiness step before formal drafting is not about creating another layer of administrative process. It is about answering a basic question: Are we actually ready to start writing? A practical readiness review can assess several areas: Are the necessary source materials available? Which documents or information are still missing? Are there material inconsistencies across different sources? Which important questions remain unresolved? Which function or subject matter expert (SME) needs to address each issue? Which unresolved issues could directly affect downstream document development? Once these questions are made visible and organized, formal writing is more likely to move forward continuously rather than repeatedly stopping while the team waits for answers. A Gap Is Not Always a Missing Document When people hear “gap analysis,” it is easy to think in terms of a checklist: Do we have a Protocol? Do we have the nonclinical reports? Do we have the PK data? But the gaps that affect document readiness are not always missing files. A gap may also mean: Two documents describe the same issue differently. The data exist, but the applicable version cannot be confirmed. Results are available, but the scientific interpretation has not yet been confirmed. A decision has been discussed verbally but has not been captured in a traceable form. Or an issue may appear important but may not actually block the currently scoped milestone. A Readiness Assessment therefore needs to go beyond identifying what is missing. It should also ask: Why does this issue matter? Who needs to address it? And how does it relate to the next development step? Organizing the Issues First Can Be Faster Than Starting to Write Immediately This can seem counterintuitive. If the objective is to complete a document quickly, why not simply begin drafting? Because when source materials are not sufficiently mature, drafting too early often shifts unresolved problems downstream rather than solving them. A writer prepares the first draft. An SME identifies an incorrect assumption. The clinical team revises the design. Another document then needs to be updated for consistency. The revised versions circulate again. In the end, this cycle may consume more time than an initial readiness review would have required. The purpose of readiness work is not to insist that every issue must be fully resolved before drafting can begin. The real objective is to distinguish among three types of questions: What is sufficiently resolved to proceed? What can be tracked while work continues? What must be answered before moving forward? That distinction is where readiness work becomes valuable from a project management perspective. AI Can Accelerate Readiness Review, but It Cannot Close Issues on Its Own AI is well suited to supporting large-scale source review, version comparison, information extraction, and inconsistency detection. It can quickly surface observations such as: “These two documents appear to contain different information.” “No supporting source for this information was identified.” “This decision does not appear to be confirmed in the available materials.” But these are still candidate issues. AI does not inherently know whether a discrepancy has already been accepted by the development team. Nor can it independently determine whether a particular gap materially affects the current development milestone. Human judgment is therefore still required to determine: Is this a genuine Readiness Issue? Who needs to confirm it? What is its priority? Does it affect the current document-development work? Does it require escalation? AI can help identify issues, but it cannot automatically declare them resolved. Document Readiness Is Part of Document Quality A high-quality clinical document is not defined only by accurate language and complete formatting. It also depends on clear sources, controlled versions, confirmed decisions, and traceable lines of responsibility. Effective document development therefore does not always begin with the first sentence of a draft. Often, it begins with an earlier question: Are the materials we have today actually ready to be incorporated into a formal document? Answering that question first can make the writing that follows substantially more efficient.

Clinical study design has never been simply about writing a Protocol. Before formal drafting begins, the development team must already address a series of interconnected questions: What is the objective of the study? Who is the target population? How should dose and administration be structured? Which safety signals need to be monitored? How should endpoints be defined? Under what circumstances should the study be stopped or modified? As generative AI enters clinical development workflows, new possibilities are emerging. AI can rapidly organize large volumes of background information, compare different design options, generate structured question lists, and help translate confirmed design decisions into a Protocol Synopsis or an initial Protocol draft. Tasks that once required substantial manual searching, organization, and repeated rewriting can now be accelerated. But this raises a more important question: AI can help design a clinical study—but should it make clinical study design decisions on behalf of humans? AI Is Best Used First for Information-Intensive Work During the early stages of study design, the first challenge is often not a lack of information, but that the information is fragmented. Scientific background, nonclinical findings, existing human data, experience with comparable products, development strategy, and input from different functional teams may be distributed across multiple documents and versions. At this stage, one of AI’s most immediate benefits is its ability to support information-intensive work. For example, AI can help organize existing evidence, compare information across sources, identify information gaps, generate a structured list of design questions, and organize confirmed inputs into a clearer study design framework. This can help a development team move more quickly from: “We have a large amount of information” to: “What do we actually need to decide?” Organizing Options Is Not the Same as Making Decisions Clinical study design quickly moves beyond information organization. Questions such as dose selection, definition of the study population, selection of the primary endpoint, dose-escalation strategy, and stopping criteria are not simply writing problems. They may simultaneously involve nonclinical evidence, clinical pharmacology, medical judgment, statistics, regulatory strategy, and the Sponsor’s assessment of the broader development program. AI can help structure these questions and generate possible options. But an answer that appears reasonable is not the same as a development decision that is ready to be adopted. A more mature workflow is therefore not: AI generates the Study Design → Human approves it Instead, it is: AI organizes evidence and options → The team identifies unresolved questions → Relevant SMEs apply professional judgment → The Sponsor confirms key development decisions → Confirmed decisions are translated into formal documents The sequence matters. Faster Document Production Makes Human Roles More Explicit As AI makes it possible to generate a Synopsis or initial Protocol draft more quickly, the scarce work begins to shift away from simply producing text. The more important questions become: Are the sources reliable? Are inputs from different functions consistent? Which elements have been confirmed? Which remain working assumptions? Who owns each decision? When does an issue need to be escalated to the appropriate SME? This is one of the implications of AI adoption in clinical development that can easily be overlooked. Production speed can increase, but decision ownership does not disappear. In fact, as documents can be generated more quickly, teams need to distinguish even more clearly between: Who produces the work, who makes the judgment, and who retains final accountability. The Value of AI Is Not to Replace Study Design, but to Make the Process More Efficient AI’s appropriate role in clinical study design should therefore not be understood as “automatically designing a clinical study.” Its more practical value is to help teams organize evidence faster, identify gaps earlier, compare options more efficiently, and translate professional decisions into documents that can be discussed, reviewed, and ultimately executed. AI can shorten the distance between information and an initial draft. But between an initial draft and an actual development decision, professional judgment from the clinical development team, the Sponsor, and the relevant SMEs remains essential. AI can accelerate the production layer of Study Design. But where the study should go remains a human decision.

When people think about AI and IND documentation, the most intuitive idea is often: “AI can help write the documents.” But if text that was previously drafted by a medical writer is simply generated by AI instead, the underlying workflow has not fundamentally changed. The greater impact of AI on IND document development may not be about who writes the words, but about changing how documents are produced. IND Documents Rarely Start from a Blank Page Protocols, Investigator’s Brochures (IBs), Informed Consent Forms (ICFs), and Pre-IND / IND-related written materials are not simply writing tasks. Before formal drafting begins, development teams typically need to work through a substantial volume of source materials: Study reports, nonclinical data, clinical pharmacology information, existing document versions, cross-functional inputs, management decisions, and revisions generated at different points in the development process. The most time-consuming questions are often not about how to phrase a particular paragraph. They are questions such as: Which version is current? Where did this number come from? Are the descriptions in the Protocol and IB consistent? Has this decision been finalized? Which SME needs to confirm this content? If these questions have not been addressed upstream, even the fastest writer is still working from immature inputs. AI First Changes the Production Layer AI is particularly well suited to supporting the repetitive and information-intensive production work involved in document development. This may include organizing source materials, extracting information, performing initial comparisons, building document structures, generating first drafts, comparing versions, and checking consistency across documents. These activities have traditionally required substantial manual effort. When AI can assist with part of this work, the distance between source materials and a first draft can be shortened. But that does not mean professional review can be removed from the downstream workflow. Quite the opposite. The faster documents can be produced, the more important review and decision control become. A Polished Draft Is Not the Same as a Usable Document Generative AI can readily produce text that is well structured and professionally written. That is both its value and its risk. When a document looks sufficiently complete, it becomes easy to mistake “written like a formal document” for “the content has been confirmed.” In clinical development, these are very different things. A document that is actually ready to move forward still needs to answer questions such as: Are the sources traceable? Is the content consistent with related documents? Have scientific conclusions been confirmed by the appropriate SMEs? Are any key decisions still open? Has the Sponsor accepted the relevant risks and assumptions? For this reason, the most appropriate role for AI output is as production input, not as final authority. The New Model Does Not Remove People—It Reallocates Their Time In traditional document-development workflows, substantial senior capacity may be consumed by information retrieval, version comparison, formatting, and repeated revision of early drafts. These activities matter, but they do not necessarily require the most senior professionals to perform every step from the beginning. An AI-assisted workflow creates another possibility: Use AI to compress repetitive production work, while preserving human capacity for source verification, cross-functional integration, professional judgment, and quality control. This is why “AI-assisted medical writing” should not be reduced to the idea of replacing medical writers with AI. The more meaningful change is a redistribution of work. From Individual Documents to Integrated Package Thinking Another easily overlooked issue is that IND documents do not exist as independent files. The study population, dose, safety monitoring, and study procedures described in a Protocol may also affect the IB, ICF, and other related materials. When each document is treated as an isolated writing task, cross-document inconsistencies can emerge. AI can assist with comparing information across these documents. But someone still needs to assess the development package as a whole and determine whether a difference represents an appropriate document-specific distinction, a version-control problem, or a genuine inconsistency that requires resolution. The emerging document-production model can therefore be summarized as: AI-Assisted Production → Clinical Development Integration → Human Review & QC What is being compressed is the document-production process—not professional review. The value of AI is not simply that documents can be written faster. It is that qualified professionals can spend more of their time on the work that actually requires judgment.